Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.65 |
| ▸ | RAB9A | P51151 | 7/20 | 0.65 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1990363 | 0.83 | NPC1 (0.69) | NPC1RAB9AEPHX2ALDH1A1HDAC3 | |
| SCHEMBL295136 | 0.83 | NPC1 (0.69) | NPC1RAB9AEPHX2ALDH1A1HDAC3 | |
| SCHEMBL693305 | 0.82 | NPC1 (0.67) | NPC1RAB9AEPHX2ALDH1A1HDAC3 | |
| Hydrochloric Acid SCHEMBL28989899 | 0.82 | NPC1 (0.67) | NPC1RAB9AEPHX2ALDH1A1HDAC3 | |
| Hydrogen Sulfide SCHEMBL5919025 | 0.82 | NPC1 (0.67) | NPC1RAB9AEPHX2ALDH1A1HDAC3 | |
| SCHEMBL680273 | 0.80 | NPC1 (0.65) | NPC1RAB9AEPHX2ALDH1A1 | |
| SCHEMBL873416 | 0.80 | NPC1 (0.65) | NPC1RAB9AEPHX2ALDH1A1HDAC3 | |
| SCHEMBL6509893 | 0.80 | NPC1 (0.65) | NPC1RAB9AEPHX2ALDH1A1HDAC3 | |
| Hydrochloric Acid SCHEMBL28063043 | 0.80 | NPC1 (0.65) | NPC1RAB9AEPHX2ALDH1A1HDAC3 | |
| SCHEMBL14852000 | 0.80 | NPC1 (0.65) | NPC1RAB9AEPHX2ALDH1A1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183276-B2 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050090534-A1 | Azole compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1486490-A1 | AZOLE COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2004-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090534-A1 | Azole compounds | AHR, NR0B2, NR2C2 | NPC1 3792/4885RAB9A 4611/4885EPHX2 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.